(Q39948374)

15 September 2017

title

Perilimbal bevacizumab injection for interface neovascularization after deep anterior lamellar keratoplasty (English)

1 reference

15 September 2017

Perilimbal Bevacizumab Injection for Interface Neovascularization After Deep Anterior Lamellar Keratoplasty (English)

1 reference

https://api.crossref.org/works/10.1097/ICO.0B013E3181D92834

3 July 2024

1 reference

1 reference

Alireza Foroutan

1

1 reference

15 September 2017

Beigzadeh Fariba

2

1 reference

15 September 2017

Bakhtiari Pejman

3

1 reference

15 September 2017

Joshaghani Mahmoud

4

1 reference

15 September 2017

Ghasemi Falavarjani Khalil

5

1 reference

15 September 2017

Ehteshami Afshar Arash

6

1 reference

15 September 2017

Pooria Foroutan

7

1 reference

15 September 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20802316

3 July 2024

publication date

1 November 2010

1 reference

full work available at URL

15 September 2017

number of pages

5

1 reference

based on heuristic

inferred from page(s)

http://journals.lww.com/00003226-201011000-00012

1 reference

https://api.crossref.org/works/10.1097/ICO.0B013E3181D92834

3 July 2024

1 reference

15 September 2017

volume

29

1 reference

15 September 2017

issue

11

1 reference

15 September 2017

page(s)

1268-1272

1 reference

Subconjunctival bevacizumab for vascularized rejected corneal grafts

15 September 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1097/ICO.0B013E3181D92834

Angiogenesis in corneal diseases: histopathologic evaluation of 254 human corneal buttons with neovascularization

3 July 2024

3

1 reference

https://api.crossref.org/works/10.1097/ICO.0B013E3181D92834

Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)

3 July 2024

4

1 reference

https://api.crossref.org/works/10.1097/ICO.0B013E3181D92834

Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis

3 July 2024

5

1 reference

https://api.crossref.org/works/10.1097/ICO.0B013E3181D92834

Subconjunctival bevacizumab for corneal neovascularization

3 July 2024

6

1 reference

https://api.crossref.org/works/10.1097/ICO.0B013E3181D92834

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

3 July 2024

7

1 reference

https://api.crossref.org/works/10.1097/ICO.0B013E3181D92834

Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin)

3 July 2024

8

1 reference

https://api.crossref.org/works/10.1097/ICO.0B013E3181D92834

Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study

3 July 2024

9

1 reference

https://api.crossref.org/works/10.1097/ICO.0B013E3181D92834

Risk factors for corneal graft failure and rejection in penetrating keratoplasty

3 July 2024

10

1 reference

https://api.crossref.org/works/10.1097/ICO.0B013E3181D92834

The effect of angiostatic steroids and beta-cyclodextrin tetradecasulfate on corneal neovascularization in the rat

3 July 2024

12

1 reference

https://api.crossref.org/works/10.1097/ICO.0B013E3181D92834

Suppressive Effects of Indomethacin on Thermally Induced Neovascularization of Rabbit Corneas

3 July 2024

14

1 reference

https://api.crossref.org/works/10.1097/ICO.0B013E3181D92834

The heparan sulfate suleparoide inhibits rat corneal angiogenesis and in vitro neovascularization

3 July 2024

15

1 reference

https://api.crossref.org/works/10.1097/ICO.0B013E3181D92834

Suppression of corneal neovascularization with cyclosporine

3 July 2024

16

1 reference

https://api.crossref.org/works/10.1097/ICO.0B013E3181D92834

Topical application of methotrexate for inhibition of corneal angiogenesis

3 July 2024

17

1 reference

https://api.crossref.org/works/10.1097/ICO.0B013E3181D92834

Thalidomide is an inhibitor of angiogenesis

3 July 2024

18

1 reference

https://api.crossref.org/works/10.1097/ICO.0B013E3181D92834

Photodynamic effect of a new photosensitizer ATX-S10 on corneal neovascularization

3 July 2024

19

1 reference

https://api.crossref.org/works/10.1097/ICO.0B013E3181D92834

Inhibition of inflammatory corneal angiogenesis by TNP-470.

3 July 2024

21

1 reference

https://api.crossref.org/works/10.1097/ICO.0B013E3181D92834

Inhibition of experimental angiogenesis of cornea by somatostatin

3 July 2024

22

1 reference

https://api.crossref.org/works/10.1097/ICO.0B013E3181D92834

Avastin use in high risk corneal transplantation

3 July 2024

23

1 reference

https://api.crossref.org/works/10.1097/ICO.0B013E3181D92834

Subconjunctival bevacizumab injection for corneal neovascularization.

3 July 2024

24

1 reference

https://api.crossref.org/works/10.1097/ICO.0B013E3181D92834

Are we getting closer to prevention and treatment of corneal neovascularization?

3 July 2024

25

1 reference

https://api.crossref.org/works/10.1097/ICO.0B013E3181D92834

Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis

3 July 2024

26

1 reference

https://api.crossref.org/works/10.1097/ICO.0B013E3181D92834

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

3 July 2024

27

1 reference

https://api.crossref.org/works/10.1097/ICO.0B013E3181D92834

Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage

3 July 2024

28

1 reference

https://api.crossref.org/works/10.1097/ICO.0B013E3181D92834

3 July 2024

Identifiers

1 reference

15 September 2017

1 reference